This study will look at how well the new medicine CagriSema helps people living with excess
body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a
dummy medicine. Which treatment they get is decided by chance.
The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or
plan to get pregnant during the study period.

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Butte

Novo Nordisk Investigational Site

Cagrilintide

Semaglutide

Placebo cagrilintide

Placebo semaglutide

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

This trial studies the side effects of radiation therapy followed by atezolizumab in treating
patients with stage II or III non-small cell lung cancer. Hyperfractionated radiation therapy
delivers smaller doses of radiation therapy over time and may kill more tumor cells and have
fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help
the body's immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. The purpose of this study is to test the safety and effectiveness of
radiation therapy followed by atezolizumab and find out what side effects, if any, it has on
patient's non-small cell lung cancer.

Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients

Kalispell

Kalispell Regional Medical Center

Atezolizumab

Hypofractionated Radiation Therapy

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status

This phase III trial compares the usual chemotherapy treatment to eribulin alone and to
eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to
other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine,
docetaxel, and paclitaxel, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
This trial aims to see whether adding eribulin to standard of care chemotherapy may work
better in treating patients with metastatic urothelial cancer.

Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Billings Metropolitan Area

Billings Clinic Cancer Center

Docetaxel

Eribulin Mesylate

Gemcitabine Hydrochloride

Paclitaxel

A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

The purpose of this study is to test the long-term safety of rimegepant in the acute
treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of
age).

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Missoula

Boeson Research MSO

Rimegepant / BHV3000

Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age.

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in
the acute treatment of moderate or severe migraine in children and adolescents.

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Rimegepant/BHV3000

Matching placebo

Phase 3, Multicenter, Randomized, Double-blind,Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of
BLU-5937 in participants with Refractory Chronic Cough (RCC).

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Montana Medical Research, Inc.

BLU-5937

Placebo

A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough

The purpose of this study is to evaluate the efficacy and safety of vericiguat in
participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically
those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart
failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that
vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart
failure hospitalization.

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

Logan Health Research ( Site 0017)

Vericiguat

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive
therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Boeson Research

Troriluzole

A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing
age. Endometriosis affects daily activities, social relationships, sexuality and sexual
activity, and mental health. This study will evaluate how well elagolix in combination with
combined oral contraceptives (COC) works within the body and/or how safe it is compared to
placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful
periods) response in participants with endometriosis and associated pain.
Elagolix is an approved drug for the management of moderate to severe pain associated with
endometriosis. Participants are randomly put in 1 of 3 groups, called treatment arms. Each
group receives a different treatment. There is a 1 in 3 chance that participants will be
assigned to placebo. Adult female participants who still have periods with a diagnosis of
endometriosis will be enrolled. Around 800 participants will be enrolled in the study at
multiple sites in the United States, including Puerto Rico.
Participants will receive oral elagolix or placebo tablets in combination with combined oral
contraceptive (COC) or placebo capsules for 3 months. All the participants will receive
elagolix tablets in combination with COC tablets from Month 4 through Month 18.
There will be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the course of the study at a
hospital or clinic. The effect of the treatment will be checked by medical assessments, blood
tests, checking for side effects and completing questionnaires.

Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Boeson Research - Missoula /ID# 248559

Elagolix

Combined Oral Contraceptive (COC)

Placebo for Elagolix

Placebo for COC

A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Combined Oral Contraceptives in Premenopausal Women With Documented Endometriosis and Associated Moderate to Severe Pain

The Fabry Registry is an ongoing, international multi-center, strictly observational program
that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of
treatment status. No experimental intervention is involved; patients in the Registry undergo
clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
-  To enhance the understanding of the variability, progression, and natural history of
Fabry disease, including heterozygous females with the disease;
-  To assist the Fabry medical community with the development of recommendations for
monitoring patients and reports on patient outcomes to help optimize patient care;
-  To characterize and describe the Fabry population as a whole;
-  To evaluate the long-term safety and effectiveness of Fabrazyme®
Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international,
longitudinal, observational, and voluntary program designed to track pregnancy outcomes for
any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving
disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and
irrespective of the commercial product with which she may be treated. Data from the
Sub-registry are also used to fulfill various global regulatory requirements, to support
product development/reimbursement, and for other research and non-research-related purposes.
No experimental intervention is given; thus a patient will undergo clinical assessments and
receive standard of care treatment as determined by the patient's physician. If a patient
consents to this Sub-registry, information about the patient's medical and obstetric history,
pregnancy, and birth will be collected, and, if a patient consents to data collection for her
infant, data on infant growth through month 36 postpartum will be collected.

Fabry Disease Registry & Pregnancy Sub-registry

Billings Clinic-Site Number:840118

Fabry Disease Registry Protocol

Montana